INTRODUCTION {#s1}
============

Vascular endothelial growth factor A (VEGFA, VEGF) is a potent inducer of blood vessel growth, but also has essential roles in neurodevelopment ([@DEV115998C18]). In humans, VEGF is encoded by a single gene (*VEGFA*) of eight exons that is alternatively spliced into isoforms, the major ones containing 121, 165 and 189 amino acid residues and therefore termed VEGF~121~, VEGF~165~ and VEGF~189~, respectively ([Fig. 1](#DEV115998F1){ref-type="fig"}A; [@DEV115998C16]). The alternatively spliced exons 6 and 7 encode domains that enable extracellular matrix (ECM) binding and additionally mediate differential binding to VEGF receptors. All VEGF isoforms bind the receptor tyrosine kinases VEGFR1 (FLT1) and VEGFR2 (KDR, FLK1), whereas the non-catalytic receptors neuropilin (NRP) 1 and NRP2 are VEGF isoform-specific receptors that preferentially bind VEGF~165~ over VEGF~121~ ([Fig. 1](#DEV115998F1){ref-type="fig"}A; [@DEV115998C13]; [@DEV115998C23]). Unexpectedly, recent studies showed that VEGF binding to NRP1 is largely dispensable for embryonic angiogenesis ([@DEV115998C10]). By contrast, VEGF signalling through NRP1 has multiple roles in neurodevelopment, including guiding migrating facial branchiomotor (FBM) neurons in the hindbrain ([@DEV115998C22]), promoting the survival of migrating gonadotropin-releasing hormone (GnRH) neurons ([@DEV115998C2]) and enhancing the contralateral projection of retinal ganglion cell (RGC) axons across the optic chiasm ([@DEV115998C6]).

To demonstrate roles for VEGF binding to NRP1 in neurons, prior studies used *Vegfa^120/120^* mice, which express VEGF~120~, the murine equivalent of VEGF~121~, but lack VEGF~164~ and VEGF~188~, corresponding to human VEGF~165~ and VEGF~189~, respectively ([@DEV115998C4]). *Vegfa^120/120^* mice phenocopy the defects of NRP1 knockouts in FBM neuron migration, GnRH neuron survival and RGC axon guidance ([@DEV115998C2]; [@DEV115998C6]; [@DEV115998C22]). In all three systems, VEGF signalling was attributed to the activity of VEGF~165~ because it evokes appropriate neuronal responses in tissue culture models ([@DEV115998C2]; [@DEV115998C6]; [@DEV115998C22]), and because the ability of NRP1 to bind VEGF~165~ is well established ([@DEV115998C10]; [@DEV115998C23]). However, *Vegfa^120/120^* mutants lack VEGF~188~ in addition to VEGF~164~. Yet, it has never previously been examined whether VEGF~189~ can also function as a NRP1 ligand *in vivo*. Moreover, it is not known whether VEGF~121~ can bind NRP1 in a physiologically relevant context, even though it has been suggested that the exon 8 domain, which is present in all major VEGF isoforms, including VEGF~121~, can mediate NRP1 binding *in vitro* ([@DEV115998C14]; [@DEV115998C19]; [@DEV115998C20]).

Here, we have generated alkaline phosphatase (AP)-conjugated VEGF isoforms for *in situ* ligand-binding assays ([@DEV115998C10]) to examine whether VEGF~121~ or VEGF~189~ can bind NRP1 *in vivo*, as previously reported for VEGF~165~. Our studies demonstrate that VEGF~189~ binds NRP1-expressing axon tracts in intact hindbrain tissue, but that VEGF~121~ is unable to do so. We further show that VEGF~188~ is co-expressed with the other isoforms during VEGF/NRP1-dependent FBM migration, GnRH neuron survival and RGC axon guidance, and that VEGF~188~ is sufficient to control all three processes, whereas VEGF~120~ is not. We conclude that VEGF~188~ effectively binds NRP1 and has the capacity to evoke NRP1-dependent signalling events, similar to VEGF~164~. Considering that VEGF~189~ has the highest affinity for ECM and therefore tissue retention amongst the VEGF isoforms, future research may therefore wish to consider the mechanistic contribution and therapeutic potential of this understudied VEGF isoform.

RESULTS AND DISCUSSION {#s2}
======================

VEGF~188~ is co-expressed with VEGF~120~ and VEGF~164~ in developing hindbrain, nose and diencephalon, and binds axons in a NRP1-dependent fashion {#s2a}
--------------------------------------------------------------------------------------------------------------------------------------------------

Because prior studies implicated VEGF signalling through NRP1 in FBM neuron migration in the hindbrain, GnRH neuron survival in the nose and RGC axon guidance in the diencephalon ([@DEV115998C2]; [@DEV115998C6]; [@DEV115998C22]), we asked which *Vegfa* isoforms were expressed in these developmental contexts. For this experiment, we designed isoform-specific primers that can distinguish the *Vegfa120*, *Vegfa164* and *Vegfa188* mRNA species by reverse transcription (RT)-PCR ([Fig. 1](#DEV115998F1){ref-type="fig"}A,B; [supplementary material Fig. S1A](supplementary material Fig. S1A)). This analysis demonstrated that all three isoforms were co-expressed during relevant periods of VEGF/NRP1-dependent neurodevelopment in mice ([Fig. 1](#DEV115998F1){ref-type="fig"}C). Fig. 1.**VEGF~189~ is expressed in developing mouse tissues and binds NRP1 in the developing hindbrain.** (A) Current knowledge of VEGF isoform binding to their receptors. All isoforms bind VEGFR1/2, whereas only VEGF~165~ is known to bind NRP1. VEGF~121~ can bind NRP1 with low affinity *in vitro*, but whether this association occurs *in vivo* has not been shown. Moreover, it has not been shown whether VEGF~189~ binds NRP1 *in vivo*. Red arrows below each isoform indicate the position of oligonucleotide primers used for RT-PCR in B. (B) *Vegfa* isoform-specific oligonucleotide primers for RT-PCR were validated with pBlueScript vectors (pBS) containing mouse *Vegfa120*, *Vegfa164* or *Vegfa188* cDNA, respectively. (C) RT-PCR analysis of the indicated tissues shows that *Vegfa120* (179 bp), *Vegfa164* (159 bp) and *Vegfa188* (215 bp) are co-expressed. (D) Whole-mount staining of E12.5 wild-type hindbrains for NRP1 and TUJ1 together with IB4; single NRP1 channels are shown in grey scale adjacent to each panel. The white arrows indicate IB4-positive vessels; the arrowhead indicates nonspecific NRP1 staining of blood cells inside mutant vessels; the red wavy arrows indicate TUJ1-positive axons; open triangles indicate absent NRP1 staining in subventricular plexus (SVP) vessels and pial axons. Scale bar: 200 μm. (E,F) AP-VEGF~121~, AP-VEGF~165~ and AP-VEGF~189~ binding to E12.5 wild-type hindbrains (E) and AP-VEGF~189~ binding to E12.5 *Nrp1^−/−^* and *Nrp2^−/−^* hindbrains (F). The white arrows indicate VEGF binding to vessels; the red wavy arrows indicate binding to axons; the open triangles indicate absence of VEGF~121~ binding to wild-type axons in E and absence of VEGF~189~ binding to axons in *Nrp1^−/−^* hindbrains in F. The arrowhead indicates vascular tufts. Scale bars: 25 μm.

Because prior studies of VEGF binding to NRP1 have not examined whether VEGF~189~ or VEGF~121~ can bind NRP1 *in vivo*, we used the mouse hindbrain as a physiologically relevant model to compare the ability of the three major VEGF isoforms to bind NRP1 in a tissue context. We first performed immunostaining with a validated antibody for NRP1 ([@DEV115998C7]) to confirm that NRP1 localises to blood vessels in wild-type, but not NRP1 knockout, hindbrains ([Fig. 1](#DEV115998F1){ref-type="fig"}D; note unspecific staining of blood in the dilated vessels of mutants). Immunolabelling also confirmed NRP1 expression in TUJ1-positive dorsolateral axons on the pial side of wild-type, but not mutant, hindbrains ([Fig. 1](#DEV115998F1){ref-type="fig"}D; [supplementary material Fig. S1B](supplementary material Fig. S1B)). *Nrp1*^−/−^ hindbrains showed some defasciculation of these dorsolateral axons, but they were still clearly present in the mutant, suggesting that this are a suitable model to examine VEGFA isoform binding to NRP1.

To compare the binding properties of VEGF~121~, VEGF~165~ and VEGF~189~, we fused each isoform to AP and performed *in situ* ligand binding assays on E12.5 hindbrains. As expected, all three isoforms bound vessels ([Fig. 1](#DEV115998F1){ref-type="fig"}E), because they express the pan-VEGF isoform receptor VEGFR2 ([@DEV115998C17]). We next examined binding to dorsolateral axons, because they express NRP1, but lack VEGFR2 ([@DEV115998C17]). Both VEGF~165~ and VEGF~189~ bound these axons, whereas VEGF~121~ did not ([Fig. 1](#DEV115998F1){ref-type="fig"}E). These observations indicate that all VEGF isoforms are capable of binding VEGFR2/NRP1-positive vessels. By contrast, only VEGF~165~ and VEGF~189~, but not VEGF~121~, bound NRP1-expressing axons lacking VEGFR2, consistent with the previously reported 10-fold lower affinity of VEGF~121~ for NRP1 *in vitro* ([@DEV115998C20]). The finding that VEGF~121~ does not bind endogenous neuronal NRP1 at detectable levels also agrees with prior genetic studies, which showed that VEGF~120~ is unable to compensate for VEGF~164~ in FBM, RGC and GnRH neurons ([@DEV115998C2]; [@DEV115998C6]; [@DEV115998C22]). Thus, low-affinity binding of VEGF~121~ to NRP1, even though previously observed *in vitro*, is unlikely to be relevant *in vivo*, at least in a neuronal context.

We next confirmed that axonal VEGF~189~ binding is NRP1 dependent. The AP ligand-binding assay showed that VEGF~189~ bound vessels ([Fig. 1](#DEV115998F1){ref-type="fig"}F) in *Nrp1*-null mutant hindbrains with their characteristic vascular tufts ([@DEV115998C8]). Strikingly, AP-VEGF~189~ failed to bind axons in *Nrp1*-null hindbrains, similar to AP-VEGF~165~ ([Fig. 1](#DEV115998F1){ref-type="fig"}F). VEGF~189~ can therefore bind axons in a NRP1-dependent fashion. By contrast, loss of NRP2 ([@DEV115998C12]) did not abolish VEGF~189~ binding ([Fig. 1](#DEV115998F1){ref-type="fig"}F). Taken together, the ligand binding assays of intact hindbrain tissue show that NRP1 serves as a neuronal receptor for VEGF~165~ and VEGF~189~, but not for VEGF~121~.

VEGF~188~ is sufficient for the NRP1-dependent migration of FBM neurons {#s2b}
-----------------------------------------------------------------------

*Vegfa* is a haploinsufficient gene for which deletion of just one allele results in early embryonic lethality due to a complete failure of blood vessel formation ([@DEV115998C3]; [@DEV115998C11]). However, retention of any one of the major VEGF isoforms rescues this severe phenotype and instead gives rise to more subtle neuronal and vascular phenotypes ([@DEV115998C21]; [@DEV115998C24]). Understanding the receptor-binding properties of the VEGF isoforms has therefore become a priority in the field. We first examined if VEGF~188~ can substitute for VEGF~164~ in FBM neuron guidance with an established hindbrain explant assay in which implanted beads provide exogenous VEGF, and FBM neuron migration is visualised by immunolabelling with the motor neuron marker ISL1 ([@DEV115998C22]; [@DEV115998C26]). Agreeing with previous observations, FBM neurons were attracted to VEGF~164~, but not to control beads lacking growth factors ([Fig. 2](#DEV115998F2){ref-type="fig"}B). VEGF~188~ beads also attracted FBM neurons ([Fig. 2](#DEV115998F2){ref-type="fig"}B). Quantification confirmed that FBM neuron migration was significantly enhanced on the hindbrain side containing a VEGF~164~- or VEGF~188~-soaked bead relative to the control side of the same hindbrain ([Fig. 2](#DEV115998F2){ref-type="fig"}C). VEGF~188~ can therefore promote NRP1-dependent neuronal migration similar to VEGF~164~. Fig. 2.**VEGF~188~ is sufficient for FBM neuron migration.** (A) Schematic representation of FBM neuron migration in the mouse. (B) ISL1 staining of E12.5 hindbrain explants containing implanted heparin beads soaked in PBS (*n*=10) or PBS containing VEGF~164~ (*n*=10) or VEGF~188~ (*n*=6). Red dotted circles indicate the position of heparin beads; white arrowheads indicate normal migration; red arrows indicate migration towards heparin beads; asterisks indicate the midline. Scale bar: 200 µm. (C) Distance migrated by FBM neurons. Migration distance was quantified as migration away from r5 territory on the hindbrain side with a bead relative to the control half of the same hindbrain; mean±s.e.m. control 1±0.09 versus VEGF~164~ bead 1.39±0.05; control 1±0.11 versus VEGF~188~ bead 2.04±0.17; \*\**P*\<0.01, VEGF compared with control (*t*-test). (D) Whole-mount *Isl1 in situ* hybridisation of E12.5 hindbrains of the indicated genotypes detects migrating FBM neurons (VIIm) (control, *n*=10; *Vegfa^120/120^*, *n*=6; *Vegfa^188/188^, n*=4; *Vegfa^120/188^*, *n*=5). Brackets indicate the width of the neuronal stream on the ventricular side; red arrowheads indicate dumbbell-shaped nuclei on the pial side; asterisks indicate the midline*.* Scale bar: 25 µm.

We next examined FBM neuron migration *in vivo* by *Isl1 in situ* hybridisation. As previously shown ([@DEV115998C22]), *Vegfa^120/120^* hindbrains demonstrated abnormal streaming of FBM neurons on the ventricular side and dumbbell-shaped nuclei on the pial side ([Fig. 2](#DEV115998F2){ref-type="fig"}D). By contrast, *Vegfa^188/188^* mice, which express only VEGF~188~, showed normal FBM neuron migration ([Fig. 2](#DEV115998F2){ref-type="fig"}D). Moreover, replacing one *Vegfa^120^* allele in *Vegfa^120/120^* mutants with the *Vegfa^188^* allele was sufficient to prevent FBM neuron defects ([Fig. 2](#DEV115998F2){ref-type="fig"}D). Unlike VEGF~120~, VEGF~188~ is therefore sufficient to direct NRP1-dependent neuronal migration.

VEGF~188~ is sufficient to guide NRP1-dependent axon crossing at the optic chiasm {#s2c}
---------------------------------------------------------------------------------

We next investigated whether VEGF~188~ can evoke neuronal responses similar to VEGF~164~ in the developing visual system. To establish binocular vision, RGC axons project through the optic chiasm to both the ipsilateral and contralateral brain hemispheres ([@DEV115998C5]). VEGF~164~, but not VEGF~120~, promotes RGC axon guidance in a NRP1-dependent fashion *in vitro*, and *Vegfa^120/120^* mice therefore develop an abnormal chiasm ([@DEV115998C6]). To examine whether VEGF~188~ can also promote RGC axon guidance, we performed DiI labelling in VEGF isoform mutants. Anterograde labelling of RGC axons from one eye at E14.5 demonstrated that VEGF~188~ was sufficient for NRP1-mediated chiasm patterning ([Fig. 3](#DEV115998F3){ref-type="fig"}A). Thus, *Vegfa^120/120^* mice had a significantly increased ipsilateral projection index as well as defasciculation of the ipsilateral and contralateral optic tracts ([@DEV115998C6]), but the ipsilateral index and shape of the optic chiasm appeared unaffected in *Vegfa^188/188^* mice ([Fig. 3](#DEV115998F3){ref-type="fig"}B,C). Moreover, replacing one *Vegfa^120^* with the *Vegfa^188^* allele was sufficient to prevent chiasm defects in *Vegfa^120/120^* mutants ([Fig. 3](#DEV115998F3){ref-type="fig"}B,C). Fig. 3.**VEGF~188~ is sufficient to guide commissural axons across the optic chiasm.** (A) Schematic illustration of the method used to anterogradely label RGC projections. DiI crystals were placed onto the retina in one eye to label axons extending through the optic chiasm into the ipsilateral and contralateral optic tracts. (B) Ipsilateral index in the indicated genotypes (mean±s.e.m.): control, 0.095±0.01, *n*=11; *Vegfa^120/120^*, 0.15±0.03, *n*=5; *Vegfa^188/188^*, 0.083±0.01, *n*=3; *Vegfa^120/188^*, 0.09±0.01, *n*=3; *t*-test, \**P*\<0.05 compared with control. (C) Whole-mount views of RGC axons at the optic chiasm from embryos of the indicated genotypes, labelled anterogradely with DiI at E14.5; ventral view, anterior upwards; optic nerve (on), contralateral optic tract (ot~c~) and ipsilateral optic tract (ot~i~). Red arrows indicate the normal position of the ipsilateral projection; red arrowheads indicate the secondary tract and axon defasciculation in *Vegfa^120/120^* mutants. Scale bar: 500 µm. Higher magnifications of each boxed areas are shown beneath the respective panels. (D) Schematic illustration of the method used to retrogradely label RGC projections. DiI crystals were placed unilaterally into the optic tract in the dorsal thalamus. (E) Proportion of ipsilaterally projecting RGCs relative to total number of RGCs in both eyes of the indicated genotypes at E15.5 (mean±s.e.m.): control, 3.28±0.44%, *n*=8; *Vegfa^120/120^*, 19.64±3.89%, *n*=4; *Vegfa^188/188^,* 2.16±0.42%, *n*=4; *Vegfa^120/188^*, 2.12±0.14%, *n*=2; *t*-test, \*\*\**P*\<0.001 compared with control. (F) Flatmounted ipsilateral retinas from E15.5 embryos of the indicated genotypes after retrograde labelling from the optic tract in the right thalamus. DT, dorsotemporal; VN, ventronasal; DN, dorsonasal; VT, ventrotemporal. Scale bar: 500 µm.

We next performed retrograde DiI labelling of RGC axons from the dorsal thalamus in VEGF isoform mice and compared the number of labelled RGCs in flatmounted ipsilateral and contralateral retina ([Fig. 3](#DEV115998F3){ref-type="fig"}D). Quantitation showed that the proportion of DiI-labelled ipsilateral RGCs was significantly increased in *Vegfa^120/120^* compared with control mice, but was normal in *Vegfa^188/188^* and *Vegfa^120/188^* mice ([Fig. 3](#DEV115998F3){ref-type="fig"}E). Flat-mount images also revealed the preferential origin of ipsilaterally projecting neurons from the ventrotemporal retina in wild types ([Fig. 3](#DEV115998F3){ref-type="fig"}F). Their distribution is affected in *Vegfa^120/120^* mice, which contain ipsilaterally projecting RGCs throughout the nasal retina ([@DEV115998C6]), but this defect was rescued by the introduction of a single *Vegfa^188^* allele ([Fig. 3](#DEV115998F3){ref-type="fig"}F). VEGF~188~ is therefore sufficient to promote NRP1-dependent aspects of optic chiasm development.

VEGF~188~ is sufficient to ensure normal GnRH neuron survival {#s2d}
-------------------------------------------------------------

As a third model to study VEGF~188~ in neurodevelopment, we investigated GnRH neuron survival. GnRH neurons are born in the nasal placode and travel along nasal axons to reach the forebrain ([Fig. 4](#DEV115998F4){ref-type="fig"}A; [@DEV115998C1]). We have previously shown that *Vegfa^120/120^* mice have significantly fewer migrating GnRH neurons and demonstrated that VEGF~164~ signals through NRP1 to promote the survival of GN11 cells, which recapitulate many features of migratory GnRH neurons ([@DEV115998C2]). We therefore examined whether VEGF~188~ promotes GN11 survival, similar to VEGF~164~. Whereas 72 h of serum withdrawal caused the death of over half of the GN11 cells, the inclusion of serum, VEGF~164~ or VEGF~188~ for the last 12 h of culture significantly reduced cell death, and VEGF~188~ was as effective as VEGF~164~ in preventing cell death; by contrast, and as expected, VEGF~120~ did not promote survival ([Fig. 4](#DEV115998F4){ref-type="fig"}B; percentage of propidium iodide-positive cells, mean±s.e.m.: control, 44±3%; serum, 2±1%; VEGF~120~, 37±3; VEGF~164~, 11±2%; VEGF~188~, 11±2%). These observations suggest that VEGF~188~, similar to VEGF~164~, can promote GnRH neuron survival. The ineffectiveness of VEGF~120~ agreed with the previously observed NRP1-dependent neuroprotection of GN11 cells and the fact that *Vegfa^120/120^* mice have fewer GnRH neurons ([@DEV115998C2]). Also in agreement with the *in vitro* findings, the GnRH neuron number was normal in *Vegfa^188/188^* mice that express VEGF~188~ but lack VEGF~164~ ([Fig. 4](#DEV115998F4){ref-type="fig"}C,D). Moreover, replacing one *Vegfa^120^* allele in *Vegfa^120/120^* mutants with the *Vegfa^188^* allele was sufficient to prevent their GnRH neuron survival defect ([Fig. 4](#DEV115998F4){ref-type="fig"}C,D). Together, these data show that VEGF~188~ is sufficient to promote NRP1-dependent neuronal survival. Fig. 4.**VEGF~188~ is sufficient to promote GnRH neuron survival.** (A) GnRH neuron migration (blue dots). The neurons are born in the nasal placodes that give rise to the olfactory and vomeronasal epithelia (OE, VNO) and migrate along olfactory and vomeronasal axons (purple, Olf/VN) through the nasal compartment (NC) to reach the forebrain (FB). (B) Serum-starved GN11 cells were treated with DMEM or DMEM-containing serum, VEGF~120~, VEGF~164~ or VEGF~188~; cell death was visualised by propidium iodide staining (red); Hoechst staining (blue) identified the total number of cells. Scale bar: 25 µm. (C) Sagittal sections of E14.5 mouse heads of the indicated genotypes, immunolabelled for GnRH. Arrows indicate migrating neurons; arrowheads indicate blood vessels; open triangles indicate the absence of migrating neurons; dotted lines indicate the FB boundary. OB, olfactory bulb. Scale bar: 100 µm. (D) GnRH neuron number in E14.5 heads of the indicated genotypes (mean±s.e.m.): control, 1246±46, *n*=6; *Vegfa^120/120^*, 854±21, *n*=5; *Vegfa^188/188^*, 1335±63, *n*=3; *Vegfa^120/188^*, 1314±58, *n*=3; *t*-test; \*\*\**P*\<0.001 compared with control.

Conclusions {#s2e}
-----------

Our study has demonstrated that human VEGF~189~, but not VEGF~121~, binds NRP1 in a tissue context, that mouse VEGF~188~ is co-expressed with VEGF~164~ in a neuronal context, and that mouse VEGF~188~ expressed from the endogenous *Vegfa* locus can evoke NRP1-dependent neuronal responses *in vitro* and *in vivo*, similar to VEGF~164~ and unlike VEGF~121~. Future work on the role of VEGF signalling through NRP1, especially studies using *Vegfa^120/120^* or tissue-specific *Vegfa*-null alleles, should therefore consider the possibility that VEGF~188~, similar to VEGF~164~, can regulate the process under investigation. This consideration would be relevant for both neural and vascular studies, or indeed any context in which VEGF signalling through NRP1 is implicated. The finding that the relatively understudied VEGF~189~ is capable of evoking VEGF isoform-specific signalling events may have broad implications for the therapeutic use of VEGF. Thus, VEGF application has been considered in many studies for pro-angiogenic, pro-neurogenic and neuroprotective therapies, e.g. the treatment of amyotrophic lateral sclerosis (reviewed by [@DEV115998C25]). Most prior studies have used VEGF~165~ to ensure comprehensive receptor targeting; however, the retention of VEGF~165~ in tissues is inferior to that of VEGF~189~ due to the presence of only one instead of two heparin/matrix-binding domains. Our work demonstrating that VEGF~189~ is fully capable of engaging NRP1, in addition to its known ability to bind VEGFR1 and VEGFR2, therefore suggests that VEGF~189~ may be better suited than VEGF~165~ to induce localised tissue effects in therapeutic applications.

MATERIALS AND METHODS {#s3}
=====================

Animals {#s3a}
-------

Animal procedures were preformed in accordance with institutional and UK Home Office guidelines. The *Vegfa^120^* and *Vegfa^188^* alleles ([@DEV115998C4]; [@DEV115998C24]), and *Nrp1^−/−^* and *Nrp2^−/−^* mice have been described previously ([@DEV115998C12]; [@DEV115998C15]).

RT-PCR and sequencing {#s3b}
---------------------

Total RNA was reverse transcribed using Superscript III (Life Technologies) and *Vegfa* isoforms amplified by PCR using MegaMix (Microzone) and the following oligonucleotide pairs: 120-F 5′-GTAACGATGAAGCCCTGGAG-3′ and 120-R 5′-CCTTGGCTTGTCACATTTTTC-3′; 164-F 5′-AGCCAGAAAATCACTGTGAGC-3′ and 164-R 5′-GCCTTGGCTTGTCACATCT-3′; 188-F 5′-AGTTCGAGGAAAGGGAAAGG-3′ and 188-R 5′-GCCTTGGCTTGTCACATCT-3′.

AP-fusion protein binding assays {#s3c}
--------------------------------

Open reading frames for the VEGF isoforms were amplified by PCR with the oligonucleotides 5′-AATAATGGATCCGCACCCATGGCAGAAGG-AG-3′ and 5′-TATATGCTCGAGCTCACCGCCTCGGCTTGTC-3′. The PCR products were cloned into pAG3-AP containing an upstream in-frame AP cassette. Binding assay were performed as described previously ([@DEV115998C9]).

Immunolabelling and *in situ* hybridisation {#s3d}
-------------------------------------------

Primary antibodies used were: rabbit anti-mouse GnRH (Immunostar, 20075, 1:1000), goat anti-rat NRP1 (R&D Systems, AF566, 1:100), rabbit anti-mouse TUJ1 (Covance, MRB-435p, 1:250) and mouse anti-rat ISL1 (DSHB, 39.4D5, 1:100). Secondary antibodies used were: Alexa594-conjugated rabbit anti-goat Fab (Jackson ImmunoResearch, 305-587-003, 1:200), Alexa488-conjugated donkey anti-rabbit Fab (Jackson ImmunoResearch, 711-547-003, 1:200), Alexa488-conjugated goat anti-mouse (Life Technologies, A-110011, 1:200) and biotinylated goat anti-rabbit (Vector Laboratories, BA-1000, 1:200). To detect blood vessels, we used biotinylated IB4 (Sigma) followed by Alexa633-conjugated streptavidin (Life Technologies). For *in situ* hybridisation, we used a digoxigenin-labelled *Isl1* probe ([@DEV115998C22]).

Hindbrain explant culture {#s3e}
-------------------------

Hindbrain explants were cultured as previously described ([@DEV115998C22]; [@DEV115998C26]). Affi-Gel heparin beads (Bio-Rad) were soaked overnight in 100 ng/ml of VEGF~164~ in PBS (Preprotech) or VEGF~188~ (Reliatech). FBM neuron migration was measured with ImageJ (NIH) as the distance travelled from r5 to the leading group of cells in r6 in each hindbrain and normalised to the control side of each hindbrain.

DiI labelling {#s3f}
-------------

DiI labelling was performed with fixed tissues as described previously ([@DEV115998C6]). Briefly, a DiI crystal (Life Technologies) was placed over the optic disc of one eye for anterograde labelling. After 3 days at 37°C, dissected brains were imaged ventral side upwards. ImageJ was used to determine the pixel intensity in defined areas of the ipsilateral and contralateral optic tracts, and the ipsilateral index calculated as the ratio of fluorescent intensity in the ipsilateral relative to the ipsilateral plus contralateral tracts. For retrograde labelling, the cortex was removed unilaterally and DiI crystals placed in a row over the dorsal thalamus for 15 weeks at room temperature; we imaged flatmounted retinas as above and determined the percentage of labelled ipsilateral RGCs relative to the ipsilateral plus contralateral RGCs.

GnRH neuron analysis and survival assays {#s3g}
----------------------------------------

Immunolabelled GnRH-positive cells were quantitated and GN11 survival assays performed as described previously ([@DEV115998C2]). For survival assays, cells were serum starved for 72 h and treated for 12 h with media containing 10% FBS, 10 ng/ml VEGF~120~, VEGF~164~ or VEGF~188~.

Supplementary Material
======================
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